QUEST DIAGNOSTICS INC 4

Director Robert B. Carter acquired 3,864 shares of Quest Diagnostics Inc. common stock via a dividend reinvestment plan on July 22, 2026.

On July 22, 2026, director Robert B. Carter of Quest Diagnostics Inc. acquired 3,864 shares of common stock through a broker-administered dividend reinvestment plan at an average price of approximately $206.804 per share, for an estimated transaction value of about $799,500. This acquisition, which is eligible for deferred reporting on Form 5 under Rule 16a-6 but was voluntarily reported early on Form 4, increases Carter’s direct ownership to at least 3,864 Quest shares, implying a post-transaction holding value of roughly $890,000 when marked to the current market price of $230.39 per share. The transaction represents a non-open-market, dividend-funded increase in exposure, rather than a discretionary open-market purchase or sale.

Filing Facts

CIK

1022079

Ticker

DGX

Form

4

Source Type

sec

Accession

0001022079-26-000085

Alert Tier

7